Autolus Therapeutics (AUTL) Share-based Compensation (2018 - 2025)

Autolus Therapeutics (AUTL) has 8 years of Share-based Compensation data on file, last reported at $3.4 million in Q4 2025.

• Quarterly Share-based Compensation fell 44.76% year-over-year to $3.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $14.4 million (down 6.68% YoY) and the FY2025 annual result came in at $14.4 million, down 6.68% from the prior year.
• Share-based Compensation eased to $3.4 million in Q4 2025, from $3.8 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $27.9 million in Q3 2021 to a low of -$18.6 million in Q4 2021.
• A 5-year average of $4.7 million and a median of $3.4 million in 2022 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2021 — Share-based Compensation plunged 267.64% — and 2024, when it surged 9993.65%.
• Tracing AUTL's Share-based Compensation over 5 years: stood at -$18.6 million in 2021, then soared by 118.38% to $3.4 million in 2022, then plunged by 101.84% to -$63000.0 in 2023, then surged by 9993.65% to $6.2 million in 2024, then sank by 44.76% to $3.4 million in 2025.
• The last three Share-based Compensation figures came in at $3.4 million (Q4 2025), $3.8 million (Q3 2025), and $4.3 million (Q2 2025), per Business Quant data.